Table1_Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders.DOCX
Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal peptide receptor 2 (VIPR2) might be an attractive drug target for the treatment of schizophrenia because both preclinical and clinical studies have demonstrated a strong link between high expression/overactivation of VIPR2 and schizophrenia. Nevertheless, VIPR2-targeting drugs are not yet available. VIPR2 is a class-B G protein-coupled receptor that possesses high structural homology to its subtypes, vasoactive intestinal peptide receptor 1 (VIPR1) and pituitary adenylate cyclase-activating polypeptide type-1 receptor (PAC1). These biological and structural properties have made it difficult to discover small molecule drugs against VIPR2. In 2018, cyclic peptide VIpep-3, a VIPR2-selective antagonist, was reported. The aim of this study was to generate a VIpep-3 derivative for in vivo experiments. After amino acid substitution and structure optimization, we successfully generated KS-133 with 1) a VIPR2-selective and potent antagonistic activity, 2) at least 24 h of stability in plasma, and 3) in vivo pharmacological efficacies in a mouse model of psychiatric disorders through early postnatal activation of VIPR2. To the best of our knowledge, this is the first report of a VIPR2-selective antagonistic peptide that counteracts cognitive decline, a central feature of schizophrenia. KS-133 may contribute to studies and development of novel schizophrenia therapeutic drugs that target VIPR2.
History
References
- https://doi.org//10.1007/s12031-018-1150-y
- https://doi.org//10.1007/s00213-014-3848-z
- https://doi.org//10.1016/j.nlm.2017.10.010
- https://doi.org//10.3389/fnins.2021.717490
- https://doi.org//10.1196/annals.1418.003
- https://doi.org//10.1038/s41537-021-00149-0
- https://doi.org//10.1002/cne.23078
- https://doi.org//10.1124/jpet.102.036129
- https://doi.org//10.1176/appi.ajp.161.4.742
- https://doi.org//10.2147/nedt.2006.2.4.531
- https://doi.org//10.1016/s0920-9964(02)00201-3
- https://doi.org//10.1007/s12035-018-0972-5
- https://doi.org//10.3389/fendo.2020.585082
- https://doi.org//10.1124/mol.109.060137
- https://doi.org//10.3389/fendo.2012.00139
- https://doi.org//10.1046/j.1460-9568.2003.02425.x
- https://doi.org//10.1016/j.bcp.2010.11.015
- https://doi.org//10.2174/1381612043384934
- https://doi.org//10.7150/thno.21254
- https://doi.org//10.1089/154065802761001356
- https://doi.org//10.1111/j.1365-2826.2007.01537.x
- https://doi.org//10.1007/s12035-016-0202-y
- https://doi.org//10.1021/ml400257h
- https://doi.org//10.1001/archpsyc.57.1.65
- https://doi.org//10.1016/s0196-9781(96)00322-1
- https://doi.org//10.1038/sj.jcbfm.9600163
- https://doi.org//10.1093/oxfordjournals.schbul.a033430
- https://doi.org//10.1002/aur.1596
- https://doi.org//10.1111/j.1476-5381.2012.01871.x
- https://doi.org//10.1016/s0092-8674(02)00736-5
- https://doi.org//10.1016/j.tips.2013.11.001
- https://doi.org//10.1007/s11095-019-2613-8
- https://doi.org//10.1002/(sici)1096-9861(19971006)386%3A4<661%3Aaid-cne11>3.0.co;2-n
- https://doi.org//10.1002/cne.20231
- https://doi.org//10.1097/00001756-200011090-00044
- https://doi.org//10.1016/j.neulet.2018.06.033
- https://doi.org//10.1111/j.1476-5381.2010.00872.x
- https://doi.org//10.1001/jamapsychiatry.2014.1582
- https://doi.org//10.1016/j.peptides.2007.04.026
- https://doi.org//10.1176/appi.ajp.2010.10060876
- https://doi.org//10.1016/j.biopsych.2015.11.012
- https://doi.org//10.1016/j.addr.2011.11.002
- https://doi.org//10.1111/bph.12955
- https://doi.org//10.1002/jps.2600760709
- https://doi.org//10.3389/fpsyt.2017.00083
- https://doi.org//10.17226/5140
- https://doi.org//10.1007/s00210-007-0232-0
- https://doi.org//10.2174/138161211795589409
- https://doi.org//10.1155/2015/708306
- https://doi.org//10.1038/s41467-020-17110-x
- https://doi.org//10.1038/mp.2009.146
- https://doi.org//10.1093/oxfordjournals.schbul.a033337
- https://doi.org//10.1016/j.bbrc.2018.07.144
- https://doi.org//10.1073/pnas.97.21.11575
- https://doi.org//10.3389/fncel.2020.00221
- https://doi.org//10.1038/npp.2009.230
- https://doi.org//10.1016/j.biopsych.2004.03.002
- https://doi.org//10.1038/sj.npp.1300120
- https://doi.org//10.3389/fnins.2020.00521
- https://doi.org//10.1016/j.pbb.2014.08.013
- https://doi.org//10.1016/j.bbi.2014.09.020
- https://doi.org//10.1016/j.neuroscience.2004.05.029
- https://doi.org//10.1038/s41380-019-0492-3
- https://doi.org//10.2337/diabetes.51.5.1453
- https://doi.org//10.1016/j.bbapap.2011.03.009
- https://doi.org//10.1038/nature09884
- https://doi.org//10.1124/pr.109.001370
- https://doi.org//10.1016/s0196-9781(97)00229-5
- https://doi.org//10.1046/j.1471-4159.1996.66041762.x
- https://doi.org//10.1159/000064942
- https://doi.org//10.1111/bph.12181
- https://doi.org//10.2174/187152710793361595
- https://doi.org//10.1111/jcpp.12457
- https://doi.org//10.1016/j.schres.2014.04.004
- https://doi.org//10.1074/jbc.M211945200
CC BY 4.0